BACKGROUND:Urinary tract infections (UTIs) are common among women and frequently recur. Depletion of vaginal lactobacilli is associated with UTI risk, which suggests that repletion may be beneficial. We conducted a double-blind placebo-controlled trial of a Lactobacillus crispatus intravaginal suppository probiotic (Lactin-V; Osel) for prevention of recurrent UTI in premenopausal women. METHODS:One hundred young women with a history of recurrent UTI received antimicrobials for acute UTI and then were randomized to receive either Lactin-V or placebo daily for 5 d, then once weekly for 10 weeks. Participants were followed up at 1 week and 10 weeks after intervention and for UTIs; urine samples for culture and vaginal swabs for real-time quantitative 16S ribosomal RNA gene polymerase chain reaction for L. crispatus were collected. RESULTS:Recurrent UTI occurred in 7/48 15% of women receiving Lactin-V compared with 13/48 27% of women receiving placebo (relative risk [RR], .5; 95% confidence interval, .2-1.2). High-level vaginal colonization with L. crispatus (≥10(6) 16S RNA gene copies per swab) throughout follow-up was associated with a significant reduction in recurrent UTI only for Lactin-V (RR for Lactin-V, .07; RR for placebo, 1.1; P < .01). CONCLUSIONS: Lactin-V after treatment for cystitis is associated with a reduction in recurrent UTI. Larger efficacy trials of this novel preventive method for recurrent UTI are warranted. CLINICAL TRIALS REGISTRATION. NCT00305227.
RCT Entities:
BACKGROUND:Urinary tract infections (UTIs) are common among women and frequently recur. Depletion of vaginal lactobacilli is associated with UTI risk, which suggests that repletion may be beneficial. We conducted a double-blind placebo-controlled trial of a Lactobacillus crispatus intravaginal suppository probiotic (Lactin-V; Osel) for prevention of recurrent UTI in premenopausal women. METHODS: One hundred young women with a history of recurrent UTI received antimicrobials for acute UTI and then were randomized to receive either Lactin-V or placebo daily for 5 d, then once weekly for 10 weeks. Participants were followed up at 1 week and 10 weeks after intervention and for UTIs; urine samples for culture and vaginal swabs for real-time quantitative 16S ribosomal RNA gene polymerase chain reaction for L. crispatus were collected. RESULTS: Recurrent UTI occurred in 7/48 15% of women receiving Lactin-V compared with 13/48 27% of women receiving placebo (relative risk [RR], .5; 95% confidence interval, .2-1.2). High-level vaginal colonization with L. crispatus (≥10(6) 16S RNA gene copies per swab) throughout follow-up was associated with a significant reduction in recurrent UTI only for Lactin-V (RR for Lactin-V, .07; RR for placebo, 1.1; P < .01). CONCLUSIONS: Lactin-V after treatment for cystitis is associated with a reduction in recurrent UTI. Larger efficacy trials of this novel preventive method for recurrent UTI are warranted. CLINICAL TRIALS REGISTRATION. NCT00305227.
Authors: David N Fredricks; Tina L Fiedler; Katherine K Thomas; Brian B Oakley; Jeanne M Marrazzo Journal: J Clin Microbiol Date: 2007-08-08 Impact factor: 5.948
Authors: Louisa Kwok; Ann E Stapleton; Walter E Stamm; Sharon L Hillier; Cheryl L Wobbe; Kalpana Gupta Journal: J Urol Date: 2006-11 Impact factor: 7.450
Authors: Sujatha Srinivasan; Congzhou Liu; Caroline M Mitchell; Tina L Fiedler; Katherine K Thomas; Kathy J Agnew; Jeanne M Marrazzo; David N Fredricks Journal: PLoS One Date: 2010-04-15 Impact factor: 3.240
Authors: Anke Hemmerling; William Harrison; Adrienne Schroeder; Jeanna Park; Abner Korn; Stephen Shiboski; Craig R Cohen Journal: Sex Transm Dis Date: 2009-09 Impact factor: 2.830
Authors: Jean M Macklaim; Craig R Cohen; Gilbert Donders; Gregory B Gloor; Janet E Hill; Groesbeck P Parham; Jacques Ravel; Gregory Spear; Janneke van de Wijgert; Gregor Reid Journal: Reprod Sci Date: 2012-05-21 Impact factor: 3.060